Safety, tolerability, pharmacokinetics and pharmacodynamics of GZR4 , a novel once‐weekly basal insulin, in healthy participants: A randomized trial
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16250 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Chengyong Tang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Phase 1 Clinical Trial Center, Bishan Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: The Scientific and Technological Project of Beijing Tongzhou District.
Abstract (Originalsprache)
Aims
Insulin GZR4 (GZR4), a novel once‐weekly basal insulin, has demonstrated a favourable safety and low toxicity profile, as well as notable in vivo glycaemic control effects, in preclinical studies. The study aimed to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GZR4 in healthy Chinese participants.
Methods
In this randomized, single‐blind, dose‐escalation Phase 1a study, healthy male adults aged 18–45 years, with a BMI of 19–24 kg/m 2 were enrolled in five cohorts. Participants in Cohorts 1–4 were randomized 4:1 to receive subcutaneous injections of GZR4 at doses of 1, 3, 6, and 12 nmol/kg or placebo. Participants in Cohort 5 received 0.4 U/kg (2.4 nmol/kg) of insulin degludec (IDeg). Euglycaemic glucose clamps were conducted 24–48 h (Day 2) and 144–168 h (Day 7) after GZR4 administration, and 0–24 h (Day 1) after IDeg administration. The primary endpoints were the safety and tolerability of GZR4.
Results
A total of 43 participants were enrolled, and 42 of them completed the study. No deaths, serious adverse events (SAEs), or discontinuations related to the investigational product were reported. The most common treatment‐emergent adverse events (TEAEs) were hypoglycaemia, which occurred exclusively in the 12 nmol/kg GZR4 group. All TEAEs were mild to moderate in severity. The PK parameters of GZR4 increased linearly with the dose from 1 to 12 nmol/kg, and the glucose‐lowering effect was sustained for approximately 1 week. The AUC GIR,24‐48h and AUC GIR,144‐168h for the 6 nmol/kg GZR4 dose (54.91 and 37.84 h × mg/kg/min) were comparable with that of IDeg (AUC GIR,0‐24h , 40.59 h × mg/kg/min), suggesting that GZR4's potency may be approximately 3.2‐times greater than IDeg weekly.
Conclusion
Once‐weekly GZR4 demonstrated good safety and tolerability in healthy participants. It exhibited a dose‐dependent and sustained glucose‐lowering effect over a full week and demonstrated stronger daily glucose‐lowering efficacy than once‐daily IDeg under similar molar concentrations. These results support further investigation of once‐weekly GZR4 for glycaemic control in patients with diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Phase 1 Clinical Trial Center, Bishan Hospital of Chongqing Medical University, Chongqing, China.
- Gan & Lee Pharmaceuticals, Beijing, China.
Förderung
- The Scientific and Technological Project of Beijing Tongzhou District
Zitieren
APA
Tang, C., Su, R., Wan, L., Zhu, M., Pu, J., Hao, C., Zhao, J., He, A., Xie, T., Li, Y., Chen, W., & Gan, Z. R. (2025). Safety, tolerability, pharmacokinetics and pharmacodynamics of GZR4 , a novel once‐weekly basal insulin, in healthy participants: A randomized trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16250
Vancouver
Tang C, Su R, Wan L, Zhu M, Pu J, Hao C, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of GZR4 , a novel once‐weekly basal insulin, in healthy participants: A randomized trial. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16250
BibTeX
@article{Tang2025,
author = {Tang, Chengyong and Su, Rui and Wan, Lei and Zhu, Mingxue and Pu, Junliang and Hao, Chunyue and Zhao, Jing and He, Anshun and Xie, Tian and Li, Yue and Chen, Wei and Gan, Zhong-Ru},
title = {Safety, tolerability, pharmacokinetics and pharmacodynamics of GZR4 , a novel once‐weekly basal insulin, in healthy participants: A randomized trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16250}
}
EUVIMED